Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
16 p, 1.0 MB Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma : A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment / Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Dimopoulos, Meletios (National and Kapodistrian University) ; Schjesvold, Fredrik (University of Oslo) ; Beksac, Meral (Ankara Üniversitesi Tip Fakültes) ; Facon, Thierry (Hôpital Claude Huriez CHU de Lille) ; Dhanasiri, Sujith (Celgene International Sàrl. a Bristol-Myers Squibb Company (Suïssa)) ; Guo, Shien (Evidera) ; Mu, Yutian (Evidera) ; Hong, Kevin (Bristol Myers Squibb) ; Gentili, Christian (Bristol Myers Squibb) ; Galli, Mónica (ASST Papa Giovanni XXIII) ; Yagci, Munci (Gazi University) ; Larocca, Alessandra (University of Torino) ; Richardson, Paul (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ; Weisel, Katja (University Medical Center Hamburg-Eppendorf (Alemanya))
Introduction: A proportion of patients with multiple myeloma (MM) are older and/or have comorbidities, requiring dose adjustments. Data from OPTIMISMM (NCT01734928) supported the use of pomalidomide, bortezomib, and dexamethasone (PVd) for treating relapsed/refractory MM. [...]
2023 - 10.1016/j.clml.2023.10.009
Clinical Lymphoma, Myeloma & Leukemia, 2023  

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.